← Leaderboards
Jae Woo Lee
University Of California, San Francisco
$6,294,028
Attributed
$7,884,876
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2008–23$2M$1.5M$1M$500K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$7,884,876 · 3
By mechanism
R01$7,276,026 · 2
K08$608,850 · 1
Top collaborators
- Perenlei Enkhbaatar5 shared
Most similar at University Of California, San Francisco
Same institution · by research overlap
- Winston Chiong$12,332,434
- Ajit Harishkumar Goenka$3,380,410
- Eric Collisson$14,159,893
- Zhen Jane Wang$4,501,373
- Neil P Shah$6,146,823
Others in their field
Top investigators on “Translations”
- Lee Marshall Nadler · Dana-Farber Cancer Inst$375,212,111
- Leonard Freedman · Leidos Biomedical Research, Inc.$362,430,297
- Eric Jeffrey Topol · Cleveland Clinic Lerner Col/Med-Cwru$293,499,096
- Steven E Reis · University Of Pittsburgh At Pittsburgh$281,789,183
- David Heimbrook · Leidos Biomedical Research, Inc.$265,645,121
- Gregory H Reaman · National Childhood Cancer Foundation$259,780,965
Research focus
TranslationsAlveolarInflammatoryProteinsLungPermeabilityPulmonary EdemaLung InjuryResearch PersonnelCytokineLiquid SubstanceTherapeutic EffectAnti-Inflammatory AgentsEdemaType Ii Epithelial Receptor CellEpithelialParacrineInjuredPropertyMesenchymal Stem CellsStem CellsEscherichia ColiInnovative TherapyBiological
Grant awards (19)
Therapeutic Use of High Molecular Weight Hyaluronic Acid in Acute Lung Injury Following Severe Bacterial Pneumonia or Sepsis$629,119
R01 · FY2023 · HL · contact PI
Therapeutic Use of High Molecular Weight Hyaluronic Acid in Acute Lung Injury Following Severe Bacterial Pneumonia or Sepsis$153,425
R01 · FY2023 · HL · contact PI
Therapeutic Use of High Molecular Weight Hyaluronic Acid in Acute Lung Injury Following Severe Bacterial Pneumonia or Sepsis$788,880
R01 · FY2022 · HL · contact PI
Therapeutic Use of High Molecular Weight Hyaluronic Acid in Acute Lung Injury Following Severe Bacterial Pneumonia or Sepsis$794,956
R01 · FY2021 · HL · contact PI
Therapeutic Use of High Molecular Weight Hyaluronic Acid in Acute Lung Injury Following Severe Bacterial Pneumonia or Sepsis$815,317
R01 · FY2020 · HL · contact PI
Human Mesenchymal Stem Cell Microvesicles for the Treatment of Acute Lung Injury$689,069
R01 · FY2020 · HL · contact PI
Human Mesenchymal Stem Cell Microvesicles for the Treatment of Acute Lung Injury$470,190
R01 · FY2019 · HL · contact PI
Human Mesenchymal Stem Cell Microvesicles for the Treatment of Acute Lung Injury$470,190
R01 · FY2018 · HL · contact PI
Human Mesenchymal Stem Cell Microvesicles for the Treatment of Acute Lung Injury$565,689
R01 · FY2017 · HL · contact PI
Human mesenchymal stem cell microvesicles for the treatment of acute lung injury$386,250
R01 · FY2016 · HL · contact PI
Human mesenchymal stem cell microvesicles for the treatment of acute lung injury$380,456
R01 · FY2015 · HL · contact PI
Human mesenchymal stem cell microvesicles for the treatment of acute lung injury$378,525
R01 · FY2014 · HL · contact PI
Human mesenchymal stem cell microvesicles for the treatment of acute lung injury$367,710
R01 · FY2013 · HL · contact PI
Human mesenchymal stem cell microvesicles for the treatment of acute lung injury$386,250
R01 · FY2012 · HL · contact PI
Mesenchymal Stem Cells for Treatment of Acute Lung Injury$121,770
K08 · FY2012 · HL · contact PI
Mesenchymal Stem Cells for Treatment of Acute Lung Injury$121,770
K08 · FY2011 · HL · contact PI
Mesenchymal Stem Cells for Treatment of Acute Lung Injury$121,770
K08 · FY2010 · HL · contact PI
Mesenchymal Stem Cells for Treatment of Acute Lung Injury$121,770
K08 · FY2009 · HL · contact PI
Mesenchymal Stem Cells for Treatment of Acute Lung Injury$121,770
K08 · FY2008 · HL · contact PI